A micro review on the role of recently emerged Artificial Intelligence (AI) tools and algorithms in microbiome-gut-brain-axis associated disease therapy via psychobiotics

Abstract

The microbiome-gut-brain axis involves the bidirectional connection between the gastrointestinal tract, gut microbiome, and central nervous system, and it is pivotal for mental well-being. Imbalances in the gut microbiome (dysbiosis) can disrupt neurotransmitter synthesis, leading to neurodegenerative diseases. Recent researches highlight psychobiotics as effective treatments for mental health conditions like depression. With advancements in artificial intelligence (AI) and large datasets, psychobiotic research has accelerated. AI tools are increasingly used for the prediction, identification, and diagnosis of gut microbiome compositions, enabling faster and more accurate discovery of therapeutic candidates. This review explores the role of AI in enhancing microbiome-gut-brain-axis-related disease therapies through psychobiotics and discusses future directions for this rapidly evolving research field.

Keywords

Artificial intelligence / Microbiome-gut-brain axis / Disease / Therapy / Psychobiotics

Declarations

Not applicable.

Authors' contributions

L.W.K. Lim: Conceptualization, Literature search and review, Writing-original draft, Writing-review & editing, Critical analysis.

Ethics approval and consent to participate

Not applicable.

Consent for publication

The author has read and approved the final manuscript, and consent to its publication.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Declaration of Competing Interest

The author declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

Not applicable.

Authors' other information

Not Applicable.

References

[1] Arif A, Garg P, Srivastava P. Microbiome-gut-brain axis: AI insights. Insights Biol Med. 2024; 8:001-010.

[2] Lim LWK. Linking microbiome to cancer: a mini-review on contemporary advances. Microbes. 2025; 6:100279.

[3] Balaprabha GR, Neerajakshi P, Kaur P, Kumar GN, RamaRao T. The maneuver of psychobiotics in the medical aid of clinical depression. Int J Pharm Res Allied Sci. 2024; 13(1):18-25.

[4] Dziedzic A, Maciak K, Kowalska KB, Galecka M, Kobierecka W, Saluk J. The power of psychobiotics in depression: a modern approach through the microbiota-gut-brain axis: a literature review. Nutrients. 2024; 16:1054.

[5] Lim LWK. K-ras proto-oncogene (KRAS): Evolutionary dissection on the indispensable predictive and prognostic cancer biomarker across 32 primates. Anim. Gene. 2023; 30:200158.

[6] Lim LWK. Comparative genomic analysis reveals the origin and global distribution of melon necrotic virus isolates. Gene Rep. 2022; 29:101685.

[7] Lim LWK. Implementation of Artificial Intelligence in Aquaculture and Fisheries: Deep Learning, Machine Vision, Big Data, Internet of Things, Robots and Beyond. J. Comput. Cogn. Eng. 2024; 3(2):112-118.

[8] Lim LWK. Recently emerged genome wide computational enhancer target prediction tools: A brief survey. Int. J. Zool. Anim. Biol. 2023; 6(1).

[9] Stevens BR, Pepine CJ, Richards EM, Kim S, Raizada MK. Depressive hypertension: a proposed human endotype of brain/gut microbiome dysbiosis. Am Heart J. 2021; 239:27-37.

[10] Westfall S, Carracci F, Estill M, et al. Optimization of probiotic therapeutics using machine learning in an artificial human gastrointestinal tract. Sci Rep. 2021; 11:1067.

[11] McCoubrey LE, Seegobin N, Elbadawi M, et al. Active machine learning for formulation of precision probiotics. Int J Pharm. 2022; 616:121568.

[12] Laterza L, Putignani L, Settanni CR, et al. Ecology and machine learning-based classification models of gut microbiota and inflammatory markers may evaluate the effects of probiotic supplementation in patients recently recovered from COVID-19. Int J Mol Sci. 2023; 24:6623.

[13] Climent-Pérez P, Martínez-González AE, Andreo-Martínez P. Contributions of artificial intelligence to analysis of gut microbiota in autism spectrum disorder: a systematic review. Children (Basel). 2024; 11(8):931.

[14] Qiu Y, Hou Y, Gohel D, Zhou Y, Xu J, Bykova M,... Cheng F. Systematic characterization of multi-omics landscape between gut microbial metabolites and GPCRome in Alzheimer's disease. Cell Rep. 2024; 43(5):114128.

[15] Peralta-Marzal L, Rojas-Velazquez D, Rigters D, Prince N, Garssen J, Kraneveld AD,... Lopez-Rincon A. A robust microbiome signature for autism spectrum disorder across different studies using machine learning. Sci Rep. 2024; 14:814.

[16] Novielli P, Romano D, Magarelli M, et al. Personalized identification of autism-related bacteria in the gut microbiome using explainable artificial intelligence. iScience. 2024; 27(9):110709.

[17] Khan SA, Gajbhiye G. AI-driven discovery of psychobiotics: predicting mental health therapeutics via multi-omics gut microbiome data and deep reinforcement learning. Int J Adv Res Sci Commun Technol. 2025; 5(1):226-227.

[18] Sabzevari M, Szedmark S, Penttila M, Jouhten P, Rousu J. Strain design optimization using reinforcement learning. PLoS Comput Biol. 2022. https://doi.org/10.1371/journal.pcbi.1010177

[19] Kyei-Baffour VO, Vijaya AK, Burokas A, Daliri EBM. Psychobiotics and the gut-brain axis: advances in metabolite quantification and their implications for mental health. Crit Rev Food Sci Nutr. 2025. https://doi.org/10.1080/10408398.2025.2459341

[20] Slykerman RF, Davies N, Vlckova K, et al. Precision psychobiotics for gut-brain axis health: advancing the discovery pipelines to deliver mechanistic pathways and proven health efficacy. Microb Biotechnol. 2025; 18(1):e70079.